

International



Lp(a) Satellite Meeting

From Bench to Bedside
Innsbruck, May 27-28, 2016

Visit <http://lpa.i-med.ac.at>

Accepted abstracts
for poster presentation



This meeting is a satellite to the 84th EAS Congress
to be held in Innsbruck from May 29 – June 1, 2016

Guidelines for posters

- All posters have to be presented in printed form
- Please prepare your poster in the **dimensions**:
Portrait style, 95 cm wide, up to 150 cm high
We suggest 90 by 130 cm
- Please include your conflict of interest statement in your poster
- Posters must be brought to the conference by the presenting author and cannot not be mailed in advance!
- The organisers are not responsible for any poster left behind at the end of the meeting.

Poster sessions

One guided poster session for poster discussion is scheduled for Friday, May 27, 2016. Presenting authors should be on location to answer questions.

Postersession: Friday, May 27, 2016 15:55 – 17:25

Poster print service

We offer a special service for poster printing at a rate of 45,- Euros. To use the service, please contact eugen.preuss@congressinfo.eu

List of accepted posters

All posters are sorted by first author and title, underlined names indicate the person submitting

1. **Low molecular weight apolipoprotein(a) phenotype as the independent risk determinant of coronary heart disease**
Afanasieva Olga, Ezhov Marat, Razova Oxana, Soboleva Daria, Pokrovsky Sergei
2. **The influence of natural dicarbonyls on lipoprotein(a) oxidation**
Afanasieva Olga, Larkin Vadim, Dmitrieva Oxana, Tikhaze Alla, Pokrovsky Sergei
3. **Lipoprotein(a) and insulin resistance: a possible inverse relationship between two well-known cardiovascular risk factors**
Argona Caterina Oriana, Imbalzano Egidio, Cairo Valentina, Mamone Federica, Conte Caterina, Saitta Antonino, Mandraffino Giuseppe
4. **Elevated Lp(a) lipoprotein levels are associated with carotid intima-media thickness in the general population**
Baragetti Andrea, Garlaschelli Katia, Liliana Grigore, Norata D. Giuseppe, Catapano L. Alberico
5. **Diet-induced weight reduction increases Lp(a) levels in type, diabetes and obesity**
Berk Kirsten, Yahya Reyhana, Verhoeven JM. Adrie, Touw Jeanette, Leijten Frank, Van Rossum EF, Liesbeth, Wester L. Vincent, Lips A. M, Pijl Hanno, Ozcan Behiye, Timman Reinier, Erhart Gertraud, Kronenberg Florian, Roeters Van Lennep Jeanine, Sijbrands JG. Eric (submitted by Monique Mulder)

6. Comparison of immunoblotting and quantitative PCR for measurement of kringle-IV type, Lp(a) isoform polymorphism in 2,400 patients of 6 ethnicities

Çakú Artuela, Koschinsky Marlys, Mcqueen Matthew, Anand Sonia, Boffa Michael, Enas Enas, Clarke Robert Wang Xingyu, Yusuf Salim, Pare Guillaume

7. Lipoprotein(a) levels in diabetic patients with peripheral artery disease

Cavarape Alessandro, Da Porto Andrea, Zuttion Francesca, Nardi Marta, Nanino Elisa, Sechi A. Leonardo

8. Familial hypercholesterolemia (FH) with elevated lipoprotein(a) levels and aggressive coronary heart disease: a casuistic approach

Dybvig S.Ane, Græsdal Asgeir

9. Lipoprotein levels in a portuguese adult population from centro hospitalar do Porto

Ferreira Lia, Ramos H. Maria, Oliveira C. José, Palma M. Isabel

10. Lipoprotein(a) – prothrombotic or not?

Gries Anna

11. A novel modified lipid tetrad index as predictor of premature coronary artery disease in Indians

Gupta Das Saswati

12. Circulating lipoprotein(a) levels and risk of cardiovascular disease: the atherosclerosis risk in communities (aric) study

Hoogeveen C. Ron, Sun Wensheng, Virani S. Salim, Ballantyne M. Christie

13. Genetic variants in LPA gene are associated with the risk of cancer in elderly Japanese population

Ikeda Shinobu, Naka Mieno Makiko, Tanaka Noriko, Kuchiba Aya, Arai Tomio, Tanaka Masashi, Muramatsu Masaaki, Sawabe Motoji

14. Small size apolipoprotein(a) isoforms enhance inflammatory and proteolytic potential of collagen-primed monocytes

Jaisson SJ. Stephane, Garnotel Roselyne, Durlach Vincent, Angles Cano Edouardo, Gillery Philippe

15. Differences in atherosclerotic vessel affections between hypercholesterolemic patients and patients with elevated lipoprotein(a)

Julius Ulrich, Schampera Steffen, Fischer Sabine

16. Effect of the probiotic drink Yakult light on lipoprotein(a) levels and other lipid parameters

Kedenko Ludmilla, Gemeier Carolin, Hackl Evelyn, Lippert Kathrin, Mühlberger Claudia, Leitner Miriam, Kedenko Igor, Kautzky-Willer Alexandra, Paulweber Bernhard

17. Elevated lipoprotein(a) and ischemic strokes- a case report

Moriarty Patrick, Sehar Nandhini, Denney Lauryn, Luna Paola, Perez-Marquez Francesca, Panchal Apurva, Moriarty Patrick

18. Very high lipoprotein(a) levels in prediction of coronary artery calcification and brachial flow-mediated dilatation in men in a 21-year follow-up. The cardiovascular risk in young Finns Study

Oikonen Mervi, Pietikäinen Matti, Hartiala Olli, Laitinen Tomi, Hutton-Kähönen Nina, Kähönen Mika, Lehtimäki Terho, Juonala Markus, Raitakari T. Olli, Viikari SA. Jorma

19. Lp(a) lowering can lead to regression of atherosclerotic plaques in coronary and carotid arteries in stable CHD patients

Pokrovsky Sergei, Ezhov Marat, Afanasieva Olga, Safarova Maya, Balakhonova Tatiana, Adamova Irina, Konovalov Gennady

20. The level of Lp(a) in men with coronary atherosclerosis and aorta aneurysm

Polonskaya YV, Kashtanova EV, Ragino YI, Kurgusov VA, Astrakova KV, Chernyavskiy AM.

21. Lp(a), autoantibodies to Lp(a) and T-helper cell subpopulations are associated with severity and progression of atherosclerosis

Pylaeva Ekaterina, Afanasieva Olga, Klesareva Elena, Arefieva Tatiana, Afanasieva Marina, Potekhina Alexandra, Provatorov Sergei, Balakhonova Tatiana, Pokrovsky Sergei

22. A systematic review and meta-analysis comparing the effects of statins and fibrates on plasma lipoprotein(a) levels

Sahebkar Amirhossein, Simental-Mendía Luis E, Banach Maciej, Serban Maria-Corina, Watts Gerald F.

23. Association of plasma lipoprotein(a) level with cancer and lung diseases

Sawabe Motoji, Mieno N. Makiko, Tanaka Noriko, Kuchiba Aya, Arai Tomio, Tanaka Masashi, Ikeda Shinobu, Muramatsu Masaaki

24. Lipoprotein(a) and cardiovascular mortality in patients at intermediate to high risk

Scharnagl Hubert, Zewinger Stephen, Speer Timo, Kleber E. Marcus, Stojakovic Tatjana, Woitas Rainer, Lepper M. Philipp, Laufs Ulrich, Silbernagel Günther, Ritsch Andreas, Filser Danilo, März Winfried

25. Neither Lp(a) nor gender influence the risk of cardiovascular disease in homozygous familial hypercholesterolaemia

Seed Mary, Thompson R. Gilbert

26. Evaluation of two methods for lipoprotein(a) determination: preliminary results

Sereni Alice, Grifoni Elisa, Marcucci Rossella, Rogolino Angela, Cellai Anna Paola, Alessandrello Liotta Agatina, Kura Ada, Abbate Rosanna, Gori Anna Maria

27. Genetic and nutritional factors determining circulating levels of lipoprotein(a): results of the “Montignoso Study”

Sereni Alice, Sticchi Elena, Gori Anna Maria, Magi Alberto, Della Latta Daniele, Chiappino Dante, Abbate Rosanna, Gensini Gian Franco, Marcucci Rossella, Sofi Francesco, Giusti Betti

28. High lipoprotein(a) levels are associated with coronary calcium score in the Montignoso Study population

Sereni Alice, Gori Anna Maria, Marcucci Rossella, Giusti Betti, Grifoni Elisa, Sofi Francesco, Chiappino Dante, Della Latta Daniele, Abbate Rosanna, Gensini Gian Franco

29. The role of Lp(a) levels and apoprotein(a) phenotype in the development of atherosclerosis in patients with coronary artery disease

Tosheska Trajkovska Katerina, Bogdanska Jasna, Alabakovska Sonja, Jovanova Silvana, Labudovic Danica

30. Comparison of cardiovascular events in patients without and with elevated lipoprotein(a) levels before and during lipoprotein apheresis (LA) treatment

Tselmin Sergey, Fischer Sabine, Hohenstein Bernd (submitted by Julius Ulrich)

31. High Lp(a) concentration effect the determination of ApoB-100 containing lipoproteins subfractions by of native electrophoresis

Utkina Elena, Afanasieva Olga, Ezhov Marat, Artemieva Nadezhda, Berestetskaya Yuliya, Adamova Irina, Pokrovsky Sergey

32. Sustained effect of PCSK9 inhibition with alirocumab on serum lipoprotein(a) levels over 78 weeks

Watts Gerald (submitted by Medica Aparna)

33. Lipoprotein(a) as a clinical decision-aid tool

Weiss C. Matthew, Gianos Eugenia, Underberg James, Berger S. Jeffrey, Weintraub Howard

34. Defining the Mechanism of Lipoprotein(a) [Lp(a)] Lowering By Alirocumab in Transgenic Mouse Models

Yeang Calvin, Miu Phuong, Simone Green, Xiaohong Yang, Ming-Yow Hung Joseph L. Witztum, Tsimikas Sotirios

35. Lipoprotein(a)-cholesterol determined by vertical auto profile correlates weakly with Lp(a) mass but modestly with HDL-C

Yeang Calvin, Tsimikas Sotirios

International



Lp(a) Satellite Meeting

From Bench to Bedside
Innsbruck, May 27-28, 2016

Together with our partners
we look forward to meeting you
in the center of the Alps at the
International Lp(a) Satellite Meeting
held in Innsbruck, Austria May 27-28, 2016.

<http://lpa.i-med.ac.at>